Viking Obesity Pill Faces Steep Climb Against Lilly's Tirzepatide, Analyst Calls Downtrend Reaction 'Extreme'
1. VKTX's Phase 2 trial data disappointed investors, showing only modest weight reduction. 2. Participants achieved up to 12.2% weight loss, but tolerability concerns surged. 3. Analysts believe stock sell-off is extreme; safety profiles showed mixed results. 4. William Blair maintains Outperform rating, citing potential M&A interest. 5. VKTX stock plummeted 41.04% to $24.82 amid market reactions.